GenSight Biologics S.A.
Developing gene therapies for neurodegenerative diseases of the eye and central nervous system.
SIGHT | PA
Overview
Corporate Details
- ISIN(s):
- FR0013183985 (+3 more)
- LEI:
- 549300NK4AB8OUEX1F54
- Country:
- France
- Address:
- 74 RUE DU FAUBOURG SAINT-ANTOINE, 75012 PARIS
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
GenSight Biologics S.A. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for retinal neurodegenerative diseases and other severe inherited diseases of the eye and central nervous system. The company leverages proprietary technology platforms, including Mitochondrial Targeting Sequence (MTS) and optogenetics, to create product candidates designed for administration as a single treatment. Its pipeline includes lenadogene nolparvovec (GS010), which is in late-stage clinical development, and GS030, currently in Phase I/II trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-30 07:30 |
Regulatory News Service
Inside Information / Other news releases
|
English | 161.2 KB | ||
| 2025-10-30 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 190.3 KB | ||
| 2025-09-29 21:50 |
Interim Report
rapport financier semestriel 2025
|
English | 769.3 KB | ||
| 2025-07-22 19:00 |
Capital/Financing Update
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | 220.0 KB | ||
| 2025-07-22 19:00 |
Share Issue/Capital Change
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
|
French | 207.1 KB | ||
| 2025-07-11 11:27 |
Major Shareholding Notification
Franchissement de seuils
|
French | 114.0 KB | ||
| 2025-07-03 21:19 |
Share Issue/Capital Change
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
|
French | 247.4 KB | ||
| 2025-07-03 21:19 |
Capital/Financing Update
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | 243.8 KB | ||
| 2025-06-26 07:30 |
Regulatory News Service
Inside Information / Other news releases
|
English | 165.8 KB | ||
| 2025-06-26 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 155.9 KB | ||
| 2025-06-12 19:02 |
Regulatory News Service
Inside Information / Other news releases
|
English | 207.0 KB | ||
| 2025-06-12 19:02 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 176.7 KB | ||
| 2025-05-13 22:00 |
Post-Annual General Meeting Information
Inside Information / Other news releases
|
English | 85.1 KB | ||
| 2025-05-13 22:00 |
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 114.2 KB | ||
| 2025-04-23 20:30 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 82.1 KB |
Automate Your Workflow. Get a real-time feed of all GenSight Biologics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GenSight Biologics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GenSight Biologics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-09 | N/A | Other | Other | 5,063,291 | 1,999,999.95 EUR |
| 2024-02-07 | N/A | Other | Other | 5,224,660 | 1,999,999.85 EUR |
| 2023-11-21 | N/A | Other | Other | 3,038,279 | 2,163,862.30 EUR |
